NCT04307134View on ClinicalTrials.gov

Besponsa Post Marketing Surveillance Study

CompletedOBSERVATIONAL

Enrollment

108

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

December 24, 2024

Study Completion Date

December 24, 2024

Conditions

Hematologic Maligmancy

Interventions

DRUG

Inotuzumab ozogamicin

R/R ALL who treated with Inotuzumab ozogamicin

Trial Locations (1)

Unknown

Pfizer, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY